Literature DB >> 18606952

Risk of upper gastrointestinal tract bleeding associated with selective serotonin reuptake inhibitors and venlafaxine therapy: interaction with nonsteroidal anti-inflammatory drugs and effect of acid-suppressing agents.

Francisco J de Abajo1, Luis A García-Rodríguez.   

Abstract

CONTEXT: Selective serotonin reuptake inhibitors have been reported to increase the risk of upper gastrointestinal tract bleeding. The wide use of these drugs makes such potential risk a public health concern, and identification of factors that may increase or minimize such risk is necessary.
OBJECTIVES: To test the association of selective serotonin reuptake inhibitors and venlafaxine hydrochloride therapy with upper gastrointestinal tract bleeding, to identify subgroups of patients at particularly increased risk, and to explore whether acid-suppressing agents may be effective in minimizing risk.
DESIGN: Nested case-control study.
SETTING: General practice database from the United Kingdom. PARTICIPANTS: One thousand three hundred twenty-one patients with upper gastrointestinal tract bleeding referred to a consultant or hospital and 10 000 control subjects matched for age, sex, and calendar year of the index date. Main Outcome Measure Risk of bleeding associated with selective serotonin reuptake inhibitors and effect of acid-suppressing agents.
RESULTS: The percentage of current users of selective serotonin reuptake inhibitors (5.3%) or venlafaxine (1.1%) among case subjects was significantly higher than in matched control subjects (3.0% and 0.3%; adjusted odds ratio [OR], 1.6; 95% confidence interval [CI], 1.2-2.1, and OR, 2.9; 95% CI, 1.5-5.6, respectively). An interaction with nonsteroidal anti-inflammatory drugs (OR, 4.8; 95% CI, 2.8-8.3) was observed, in particular among those not using acid-suppressing agents (OR, 9.1; 95% CI, 4.8-17.3) compared with users of these drugs (OR, 1.3; 95% CI, 0.5-3.3). In addition, an interaction with antiplatelet drugs in nonusers of acid-suppressing agents was suggested (OR, 4.7; 95% CI, 2.6-8.3) compared with users of these drugs (OR, 0.8; 95% CI, 0.3-2.5).
CONCLUSIONS: Antidepressants with a relevant blockade action on the serotonin reuptake mechanism increase the risk of upper gastrointestinal tract bleeding. The increased risk may be of particular relevance when these drugs are associated with nonsteroidal anti-inflammatory drugs. Our study findings also provide evidence that use of acid-suppressing agents limits such increased risk.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18606952     DOI: 10.1001/archpsyc.65.7.795

Source DB:  PubMed          Journal:  Arch Gen Psychiatry        ISSN: 0003-990X


  35 in total

Review 1.  Clinically significant drug interactions with newer antidepressants.

Authors:  Edoardo Spina; Gianluca Trifirò; Filippo Caraci
Journal:  CNS Drugs       Date:  2012-01-01       Impact factor: 5.749

Review 2.  Anticoagulation and psychotropic medications.

Authors:  Maurice Bachawati
Journal:  Curr Psychiatry Rep       Date:  2010-06       Impact factor: 5.285

3.  SSRI and the risk of gastrointestinal bleed: more than what meets the eye.

Authors:  Rubin Bahuva; Jimmy Yee; Supriya Gupta; Ashish Atreja
Journal:  Am J Gastroenterol       Date:  2015-02       Impact factor: 10.864

4.  Treating depression in older adults with dementia.

Authors:  Eric J Lenze
Journal:  J Am Geriatr Soc       Date:  2011-04       Impact factor: 5.562

5.  Venlafaxine-Induced Bruising: A Case Report.

Authors:  Jasmine E Carpenter; Juliette Fombi; Otoobong Udoka; Vicenzio Holder-Perkins
Journal:  Prim Care Companion CNS Disord       Date:  2016-05-05

Review 6.  Psychiatric comorbidity in the treatment of patients with inflammatory bowel disease.

Authors:  Branislav R Filipovic; Branka F Filipovic
Journal:  World J Gastroenterol       Date:  2014-04-07       Impact factor: 5.742

7.  Concomitant use of SSRIs, NSAIDs/aspirin and gastroprotective drugs among residents of long-term care facilities: a medical record review.

Authors:  J Simon Bell; Heidi T Taipale; Helena Soini; Kaisu H Pitkälä
Journal:  Clin Drug Investig       Date:  2011       Impact factor: 2.859

8.  Selective Serotonin Reuptake Inhibitors and Intracerebral Hemorrhage Risk and Outcome.

Authors:  Li Liu; Matthew Fuller; Tyler P Behymer; Yisi Ng; Thomas Christianson; Shreyansh Shah; Nicolas Kon Kam King; Daniel Woo; Michael L James
Journal:  Stroke       Date:  2020-03-04       Impact factor: 7.914

Review 9.  Canadian clinical practice guidelines for the management of anxiety, posttraumatic stress and obsessive-compulsive disorders.

Authors:  Martin A Katzman; Pierre Bleau; Pierre Blier; Pratap Chokka; Kevin Kjernisted; Michael Van Ameringen; Martin M Antony; Stéphane Bouchard; Alain Brunet; Martine Flament; Sophie Grigoriadis; Sandra Mendlowitz; Kieron O'Connor; Kiran Rabheru; Peggy M A Richter; Melisa Robichaud; John R Walker
Journal:  BMC Psychiatry       Date:  2014-07-02       Impact factor: 3.630

Review 10.  Escitalopram versus other antidepressive agents for depression.

Authors:  Andrea Cipriani; Claudio Santilli; Toshi A Furukawa; Alessandra Signoretti; Atsuo Nakagawa; Hugh McGuire; Rachel Churchill; Corrado Barbui
Journal:  Cochrane Database Syst Rev       Date:  2009-04-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.